“We are excited to receive this important funding from NRC IRAP for the development of our COVID-19 vaccine candidate,” said Alexander Graves, president and CEO of Symvivo Corporation. “It is our hope that the promise shown with bacTRL-Spike in preclinical models, particularly its ability to generate a mucosal immune response, will continue in first-in-human trials. We are grateful to the NRC for supporting further investigation of bacTRL-Spike as we initiate our first Phase I trial of the vaccine candidate this quarter.”